Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy

Authors:

Patterson K, Prabhu V, Xu R, Li H, Meng Y, Zarabi N, Zhong Y, Batteson R, Pellissier J, Keefe S, Grivas P and de Wit R.

Publication type:

Journal article

Publication name:

European Urology Oncology

Citation:

Patterson K, Prabhu V, Xu R, Li H, Meng Y, Zarabi N, Zhong Y, Batteson R, Pellissier J, Keefe S, Grivas P and de Wit R. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy. European Urology Oncology. 2018.

Link to publication ⟶

⟵ Back to Search Results